Design and Synthesis of Novel 5,6,7,8-Tetrahydropyrido[2,3-D]pyrimidine Derivatives as VCP/p97 Inhibitors for the Treatment of Acute Myeloid Leukemia (AML)
Drug Design, Development and Therapy · 2025-05 · Volume 19 · 4457-4479
DOI: 10.2147/dddt.s509036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-05. Verfasst von Xueyuan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Nanjing Normal University, Nanjing, 210037, People's Republic of China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents, Pyrimidines, Drug Design. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science, Nanjing Normal University, Nanjing, 210037, People's Republic of China.
- College of Science, Nanjing Forestry University, Nanjing, 210037, People's Republic of China.
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd., Nanjing, 210046, People's Republic of China.
Zitieren
APA
Wang, X., Long, Z., Wen, T., Miao, H., Ye, X., Lei, M., & Zhu, Y. (2025). Design and Synthesis of Novel 5,6,7,8-Tetrahydropyrido[2,3-D]pyrimidine Derivatives as VCP/p97 Inhibitors for the Treatment of Acute Myeloid Leukemia (AML). Drug Design, Development and Therapy, Volume 19, 4457-4479. https://doi.org/10.2147/dddt.s509036
Vancouver
Wang X, Long Z, Wen T, Miao H, Ye X, Lei M, et al. Design and Synthesis of Novel 5,6,7,8-Tetrahydropyrido[2,3-D]pyrimidine Derivatives as VCP/p97 Inhibitors for the Treatment of Acute Myeloid Leukemia (AML). Drug Design, Development and Therapy. 2025;Volume 19:4457-4479. doi:10.2147/dddt.s509036
BibTeX
@article{Wang2025,
author = {Wang, Xueyuan and Long, Zebo and Wen, Tiantian and Miao, Hang and Ye, Xinran and Lei, Meng and Zhu, Yongqiang},
title = {Design and Synthesis of Novel 5,6,7,8-Tetrahydropyrido[2,3-D]pyrimidine Derivatives as VCP/p97 Inhibitors for the Treatment of Acute Myeloid Leukemia (AML)},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {4457--4479},
doi = {10.2147/dddt.s509036}
}
EUVIMED